Literature DB >> 24058388

Patterns of care in older patients with squamous cell carcinoma of the head and neck: a surveillance, epidemiology, and end results-medicare analysis.

Noam A VanderWalde, Anne-Marie Meyer, Huan Liu, Seth D Tyree, Leah L Zullig, William R Carpenter, Carol D Shores, Mark C Weissler, David N Hayes, Mary Fleming, Bhishamjit S Chera.   

Abstract

BACKGROUND: There is growing evidence in the literature that older patients may not benefit from more intensive therapy for head and neck squamous cell carcinoma (HNSCC). A growing number of patients with HNSCC are age 65 years or older; however, much of the evidence base informing treatment decisions is based on substantially younger and healthier clinical trial populations. The purpose of this study was to assess the patterns of care of older HNSCC patients to better understand how age is associated with treatment decisions.
METHODS: Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database (1992–2007), we identified patients with non-metastatic HNSCC (n = 10,867) and categorized them by treatment: surgery vs. non-surgery and chemoradiotherapy (CRT) vs. radiotherapy (RT). Multivariate logistic regression models were used to identify variables associated with the receipt of surgery and CRT.
RESULTS: Increasing age was associated with decreased odds of receiving CRT (OR = 0.94; 95% CI 0.93–0.94) but not surgery (OR 1.00; 95% CI 0.99–1.00). Co-morbidity and race were not associated with receipt of either surgery or CRT. Utilization of CRT increased while surgery decreased between 1992 and 2007.
CONCLUSION: Age may influence the receipt of CRT for older HNSCC patients. There has been an increasing trend in the receipt of CRT and a decrease in primary surgery.

Entities:  

Mesh:

Year:  2013        PMID: 24058388      PMCID: PMC3775263          DOI: 10.1016/j.jgo.2013.03.002

Source DB:  PubMed          Journal:  J Geriatr Oncol        ISSN: 1879-4068            Impact factor:   3.599


  28 in total

1.  Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Authors:  Joan L Warren; Carrie N Klabunde; Deborah Schrag; Peter B Bach; Gerald F Riley
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

2.  Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly.

Authors:  Stephanie A Michal; David J Adelstein; Lisa A Rybicki; Cristina P Rodriguez; Jerrold P Saxton; Benjamin G Wood; Joseph Scharpf; Denise I Ives
Journal:  Head Neck       Date:  2011-10-22       Impact factor: 3.147

Review 3.  Cancer in the elderly: why so badly treated?

Authors:  I S Fentiman; U Tirelli; S Monfardini; M Schneider; J Festen; F Cognetti; M S Aapro
Journal:  Lancet       Date:  1990-04-28       Impact factor: 79.321

4.  Race and age disparities in receipt of sentinel lymph node biopsy for early-stage breast cancer.

Authors:  Katherine E Reeder-Hayes; John Bainbridge; Anne Marie Meyer; Keith D Amos; Bryan J Weiner; Paul A Godley; William R Carpenter
Journal:  Breast Cancer Res Treat       Date:  2011-02-22       Impact factor: 4.872

5.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

6.  Patterns of care in elderly head-and-neck cancer radiation oncology patients: a single-center cohort study.

Authors:  Shao Hui Huang; Brian O'Sullivan; John Waldron; Gina Lockwood; Andrew Bayley; John Kim; Bernard Cummings; Laura A Dawson; Andrew Hope; John Cho; Ian Witterick; Eric X Chen; Jolie Ringash
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-13       Impact factor: 7.038

7.  Racial/Ethnic disparities in socioeconomic status, diagnosis, treatment and survival among medicare-insured men and women with head and neck cancer.

Authors:  Xianglin L Du; Chih-Chin Liu
Journal:  J Health Care Poor Underserved       Date:  2010-08

8.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

Authors:  Jean-Pierre Pignon; Aurélie le Maître; Emilie Maillard; Jean Bourhis
Journal:  Radiother Oncol       Date:  2009-05-14       Impact factor: 6.280

9.  Head and neck cancer in the elderly: a retrospective study over 10 years (1999 - 2008).

Authors:  Astrid L Kruse; Marius Bredell; Heinz T Luebbers; Klaus W Grätz
Journal:  Head Neck Oncol       Date:  2010-10-05

10.  Utility of the SEER-Medicare data to identify chemotherapy use.

Authors:  Joan L Warren; Linda C Harlan; Angela Fahey; Beth A Virnig; Jean L Freeman; Carrie N Klabunde; Gregory S Cooper; Kevin B Knopf
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

View more
  10 in total

1.  Variation in treatment and outcome in the early stage oral cavity squamous cell carcinoma.

Authors:  Darragh S Gogarty; Paul Lennon; Sandra Deady; J Barry O'Sullivan; Orla McArdle; Mary Leader; Patrick Sheahan; James Paul O'Neill
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-23       Impact factor: 2.503

2.  Importance of Radiation Oncologist Experience Among Patients With Head-and-Neck Cancer Treated With Intensity-Modulated Radiation Therapy.

Authors:  Isabel J Boero; Anthony J Paravati; Beibei Xu; Ezra E W Cohen; Loren K Mell; Quynh-Thu Le; James D Murphy
Journal:  J Clin Oncol       Date:  2016-01-04       Impact factor: 44.544

3.  Treatment selection in oropharyngeal cancer: a surveillance, epidemiology, and end results (SEER) patterns of care analysis.

Authors:  Nitin A Pagedar; Catherine Chioreso; Jennifer A Schlichting; Charles F Lynch; Mary E Charlton
Journal:  Cancer Causes Control       Date:  2017-08-16       Impact factor: 2.506

4.  Aspiration pneumonia after concurrent chemoradiotherapy for head and neck cancer.

Authors:  Beibei Xu; Isabel J Boero; Lindsay Hwang; Quynh-Thu Le; Vitali Moiseenko; Parag R Sanghvi; Ezra E W Cohen; Loren K Mell; James D Murphy
Journal:  Cancer       Date:  2014-12-23       Impact factor: 6.860

5.  Priorities, concerns, and regret among patients with head and neck cancer.

Authors:  Melina J Windon; Gypsyamber D'Souza; Farhoud Faraji; Tanya Troy; Wayne M Koch; Christine G Gourin; Ana P Kiess; Karen T Pitman; David W Eisele; Carole Fakhry
Journal:  Cancer       Date:  2019-01-15       Impact factor: 6.860

6.  Positron emission tomography and stage migration in head and neck cancer.

Authors:  Noam A VanderWalde; Ramzi G Salloum; Tsai-Ling Liu; Mark C Hornbrook; Maureen C O'Keeffe Rosetti; Debra P Ritzwoller; Paul A Fishman; Jennifer Elston Lafata; Amir H Khandani; Bhishamjit S Chera
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-07       Impact factor: 6.223

7.  Increasing prevalence of human papillomavirus-positive oropharyngeal cancers among older adults.

Authors:  Melina J Windon; Gypsyamber D'Souza; Eleni M Rettig; William H Westra; Annemieke van Zante; Steven J Wang; William R Ryan; Wojciech K Mydlarz; Patrick K Ha; Brett A Miles; Wayne Koch; Christine Gourin; David W Eisele; Carole Fakhry
Journal:  Cancer       Date:  2018-04-30       Impact factor: 6.860

8.  Activation of Akt at T308 and S473 in alcohol, tobacco and HPV-induced HNSCC: is there evidence to support a prognostic or diagnostic role?

Authors:  Mohammad R Islam; Ian R Ellis; Michaelina Macluskey; Lynda Cochrane; Sarah J Jones
Journal:  Exp Hematol Oncol       Date:  2014-10-17

9.  Treatment tolerability and outcomes in elderly patients with head and neck cancer.

Authors:  Daniel R Dickstein; Marc Egerman; Erica Monrose; Achintya Varma; Umut Ozbek; Sonam Sharma; Jerry T Liu; Vishal Gupta; Marshall R Posner; Krzysztof Misiukiewicz; Brett A Miles; Eric Genden; Richard L Bakst
Journal:  Head Neck       Date:  2020-12-08       Impact factor: 3.821

Review 10.  The Multidisciplinary Team (MDT) Approach and Quality of Care.

Authors:  Miren Taberna; Francisco Gil Moncayo; Enric Jané-Salas; Maite Antonio; Lorena Arribas; Esther Vilajosana; Elisabet Peralvez Torres; Ricard Mesía
Journal:  Front Oncol       Date:  2020-03-20       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.